Experts Highlight Advances and Future Directions for Adjuvant Ribociclib in HR+/HER2– Breast Cancer
On September 17, 2024, the FDA approved ribociclib (Kisqali), a CDK4/6 inhibitor, for the adjuvant treatment of patients with HR-positive, HER2-negative early breast cancer based on data from the phase 3 NATALEE trial (NCT03701334). At the 2024 San …